An innovative technology

to treat serious illnesses

Buccal administration to deliver pharmaceutical active ingredients to all cells:
Interfering RNAs, metal ions, peptides …
With AONYS delivery platform, Medesis Pharma paves the way for new treatments !


New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients

March, 2023

Read more

Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases 

November, 2022

Read more

Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy

April 5, 2022

Read more

AONYS®, a unique platform for drug administration

AONYS® is a micro-emulsion for buccal administration, invisible to immune system and protected transport in HDL lipoproteins, allowing intracellular release with passage across the blood–brain barrier.

Our Goals

Medesis Pharma is a clinical-stage Pharmaceutical Biotechnology company developing innovative technology (AONYS®) for the delivery of therapeutic molecules to treat diseases with no current efficacious treatment.


Neurodegenerative diseases





About us

A nuclear threat spurs Medesis to advance radiation therapy
About us